anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Studies by Comparative Genome Hybridization (CGH) have shown that 6p22 is frequently amplified in invasive urinary bladder cancer. The E2F3 gene maps to 6p22 and encodes a transcription factor important for cell cycle regulation and DNA replication. To determine whether E2F3 resides in the 6p22 amplicon, 7 primary tumors and 3 cell lines known to have 6p22 amplification by CGH were examined by fluorescence in situ hybridization (FISH) using an E2F3-specific probe. All ten 6p22 amplified tumors showed E2F3 amplification. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for FISH and immunohistochemical expression analysis. E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (p<0.0001 each). Only 4 of 398 pTaG1/G2 tumors (1%) but 110 of 489 pT1-4 carcinomas (22%) had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (p<0.0001 each). To evaluate whether E2F3 expression would correlate with tumor proliferation, the Ki67 labeling index (LI) was analyzed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (p<0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors.
BACKGROUND & AIMS: HBV infection initiates autoimmune responses, leading to autoantibody generation. This research explores the role of autoantibodies in HBV-related Acute-on-Chronic Liver Failure (ACLF), offering novel perspectives for clinical management.
METHOD: We applied immunoprecipitation and iTRAQ techniques to screen for autoantibodies in serum from HBV-related cirrhosis patients and conducted detection with conformation- stabilizing ELISA in a cohort of 238 HBV-infected individuals and 49 health controls. Our results were validated in a retrospective cohort comprising 106 ACLF patients and further assessed through immunohistochemical analysis in liver tissues from an additional 10 ACLF cases.
RESULTS: Utilizing iTRAQ, we identified Argonaute1-3 autoantibodies (AGO-Abs) in this research. AGO2-Abs notably increased in cirrhosis, decompensation, and further in ACLF, unlike AGO1-Abs and AGO3-Abs. This reflects disease severity correlation. Logistic regression and COX models confirmed AGO2-Abs as independent prognostic indicators for decompensated liver cirrhosis (DLC) and ACLF. In the ROC analysis, AGO2-Abs showed significant diagnostic value for predicting 28- and 90-day mortality (AUROC = 0.853 and 0.854, respectively). Furthermore, combining AGO2-Abs with the Child-Pugh, MELD, and AARC scores significantly improved their predictive accuracy (P < 0.05). Kaplan-Meier analysis showed poorer survival for AGO2-Abs levels above 99.14μg/ml. These findings were supported by a retrospective validation cohort. Additionally, immunohistochemistry revealed band-like AGO2 expression in periportal liver areas, with AGO2-Abs levels correlating with total bilirubin, indicating a potential role in exacerbating liver damage through periportal functions.
CONCLUSIONS: AGO2-Abs is a robust biomarker for predicting the mortality of patients with HBV-related ACLF.
Single arm: subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
PROBLEM TO BE SOLVED: To obtain an evaluation method in which the quality of royal jelly can be evaluated by a method, wherein the decomposition of a protein in the royal jelly is used as an index. SOLUTION: In this evaluation method for the quality of royal jelly, the decomposition of a protein in the royal jelly is used as an index. That is to say, the constitution of the protein is analyzed through electrophoresis, chromatography or the like, the protein content which is estimated as an effective component is measured, and the quality is evaluated. When electrophoresis is performed, protein as the effective component forms a single band. When the contained component of the protein is numerous, effect such as an antifatigue action or the like is made proportionately large. Reduction in its content becomes the index of the degradation of the protein. The molecular weight of the protein as the index is, e.g. about 51 kilodatons, and modified polyacryalamide gel electrophoresist is preferable.  In addition, the protein as the index of the degradation can be discriminated and quantitatively determined also by chromatography, such as gel filtration chromatography or the like. Consequently, on the basis of the analyzed result, the quality of the royal jelly can be controlled, and the effect of the royal jelly can be discriminated and evaluated.
An anti-diarrhea composition comprises diarrhea symptom-reducing amounts of a powdered absorptive material capable of absorbing pathogenic intestinal bacteria, a sodium salt, a potassium salt and a sugar. The absorptive material may be Smectite or mormoiron attapulgite. The salts are preferably NaCl and KCl, with NaHCO3 also being present. Suitable sugars are glucose and dextrose. The composition may also contain a suspending agent, a coloring agent, a flavoring agent and a sweetening agent. It may be packaged in solid form for admixture with water prior to administration and is preferably moisture protected, for example by the nature of the packaging or by inclusion of a dessicant. The absorptive material may be packaged separately from the salts and sugar. On admixture with water for adminstration, the composition preferably contains, per liter, 2.5 to 15 g of absorptive material, 10 to 30 g of glucose, 60 to 120 mEq of Na+, 10 to 50 mEq of HCO- and 10 to 30 mEq of K+.
Objective: To discern the potential mechanism(s) by which high saturated fat feeding disrupts normal skeletal muscle metabolism. Our working hypothesis is that high saturated fat feeding increases gut permeability and blood endotoxin, which elicits pro-inflammatory signaling in skeletal muscle and alters the normal adaptive response to a meal. Preliminary evidence using a model of acute (5 days), high saturated fat feeding, isocaloric to habitual intake, in healthy, non-obese humans is presented herein to support this hypothesis.

Background: The inability for skeletal muscle to adapt fuel oxidation to fuel availability is termed metabolic inflexibility, a well characterized feature of disease states such as obesity, metabolic syndrome, and type 2 diabetes (T2D). The mechanism(s) responsible for skeletal muscle metabolic inflexibility are not known. Recently, there has been growing interest in the role of gut permeability and blood endotoxin in the pathology of metabolic derangements associated with obesity and T2D. Rodent studies have revealed direct links between the gut microbiome and metabolic disease, as well as associations between elevated blood endotoxin and metabolic dysregulation, both at the whole body and tissue level. High fat feeding in rodents is known to elicit elevated levels of blood endotoxin, a phenomenon that is termed metabolic endotoxemia. In humans, obesity and T2D are associated with increased blood endotoxin and single meals have been shown to elevate blood endotoxin, but to date, there is no evidence in humans that high fat feeding results in metabolic endotoxemia. Moreover, there are no established links between gut permeability, metabolic endotoxemia, and skeletal muscle metabolic function in humans.

Approach. We are proposing to utilize a model of acute high fat feeding in healthy humans to study the interplay between gut function, blood endotoxin, and skeletal muscle pro-inflammatory signaling and metabolic adaptability. We will employ a two-week lead-in period, during which research participants will be fed prepared meals that are isocaloric to their habitual diet, followed by five days of high saturated fat feeding. The high saturated fat feeding period will consist of prepared meals that are isocaloric to habitual diet with a macronutrient composition of 50% fat (45% of which will be saturated fat), 35% carbohydrate, and 15% protein. Studying healthy, nonobese humans in this context is an innovative approach on two levels: 1) any confounding influences associated with metabolic disease (obesity, diabetes, or metabolic syndrome) are eliminated, e.g., insulin resistance, hyperlipidemia, impaired gut function, pre-existing metabolic dysfunction and inflammatory tone; and 2) the isocaloric feeding design negates the confounding influence of a positive energy balance and allows us to specifically examine the effects of acutely increasing dietary saturated fat.
A time specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% byweight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% byweight, withrespect to the core; the outer coating accounts for 5-500 % byweight, withrespect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals. A time specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% byweight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% byweight, withrespect to the core; the outer coating accounts for 5-500 % byweight, withrespect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals. A compound of formula (I) and salts thereof are provided: wherein A is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
Patients receive a myeloablative conditioning regimen with PTCy or alpha beta T cell depletion at the discretion of the treating provider. Patients then undergo haploHCT on day 0. Patients undergoing myeloablative conditioning regimen with PTCy also receive GVHD prophylaxis on days 3-5. Patients undergo lumbar puncture, bone marrow aspiration, and ECHO or MUGA during screening. Patients also undergo collection of blood throughout the trial.
FIELD: immunology, immunochemistry, oncology. SUBSTANCE: invention relates to preparing antigen used for animal immunization. For this purpose human fetus meconium extract is used in mixture with specific antiserum to beta-2-MA. Formed suspension precipitate is washed out from additional components and beta-2-MA is isolated by dissociation of immune complex in acid medium, pH 2.2-2.0. Invention can be used for development of industrial technology for production of immunochemical test-systems for beta-2-MA assay in histology for diagnosis of primary and metastatic neoplasmas. EFFECT: increased yield, improved method of preparing. 1 dwg, 1 tbl
<P>PROBLEM TO BE SOLVED: To provide methods for making and using therapeutic formulations of proteosome-based immunoactive compositions.  <P>SOLUTION: There are provided compositions, wherein immunogenic compositions including proteosomes and liposaccharides are used to induce or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen are used to induce a specific adaptive immune response. Furthermore, the compositions can alter hyperreactive responses or inflammatory immune responses, such as allergic reactions. The compositions are used as a prophylactic or in various clinical situations to treat or prevent infectious diseases (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).  <P>COPYRIGHT: (C)2011,JPO&INPIT
Dose Escalation will evaluate the safety, tolerability, and immunogenicity of single adjuvanted doses of the FP conjugate, Trimer 4571 or Trimer 6931 vaccines, in a dose-escalation design. Each product must be assessed as safe prior to use in Prime Boost Regimen.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to anesthesiology and resuscitation, traumatology and orthopedics, and can be used in the prevention and treatment of venous thromboembolic complications (VTEC) in patients with spinal cord injury (SCI) of the cervical region in the acute and early periods. To achieve this, a prophylactic dose of anticoagulants is administered, the state of the hemostasis system is monitored by low-frequency piezothromboelastography (LPTEG) on the 1st, 3rd, 7th, 10th, 15th, 20th days, and an ultrasound examination (ultrasound) of the veins is performed on the 1st day. If normocoagulation, normoaggregation are detected and there is no data on venous thrombosis and thromboembolic complications (VTEC) according to the results of ultrasound, the introduction of a prophylactic dose of anticoagulants is continued. When VTEC is detected according to ultrasound of the veins, a therapeutic dose of anticoagulants is administered, regardless of the indicators of the state of the hemostasis system, until stable hypocoagulation is achieved. If normocoagulation and hyperaggregation are detected, a prophylactic dose of anticoagulants is administered in combination with antiplatelet drugs. If normocoagulation and hypoaggregation are detected, a prophylactic dose of anticoagulants is administered. When hypercoagulation and normoaggregation are detected, a therapeutic dose of anticoagulants is administered. If hypocoagulation and normoaggregation are detected, a prophylactic dose of anticoagulants is administered. When hypercoagulation and hyperaggregation are detected, a therapeutic dose of anticoagulants is administered in combination with antiplatelet drugs. If hypocoagulation and hypoaggregation are detected, a prophylactic dose of anticoagulants is administered. LPTEG and correction of antithrombotic therapy according to the monitoring data are carried out until the reference values ​​of the indicators of the state of the hemostasis system are reached, and then again on the 1st, 3rd, 7th, 10th, 15th, 20th days. Ultrasound of the veins is carried out further every 10 days.EFFECT: method provides at early stages, before clinical manifestations of thrombosis, to assess the state of hemostasis at a specific point in time and to carry out the necessary correction of therapy, taking into account the individual characteristics of the vascular-platelet component of hemostasis of a particular patient, preventing thrombosis and minimizing the risk of bleeding.1 cl, 7 tbl, 8 ex
The invention provides a method of inducing CD8+ T lymphocytes selective for a pathologically aberrant cell ex vivo. The method consists of contacting an apoptotic pathologically aberrant cell with a mixture having at least dendritic cells (DC), CD4+ T cells and CD8+ T lymphocytes, and culturing an apoptotic pathologically aberrant cell with the mixture for sufficient time to generate CD8+ T lymphocytes (TL) having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell. The invention further provides a method of inducing CD8+ TL selective for one or more target antigens ex vivo. The method consists of contacting one or more target antigens with a mixture having at least dendritic cells (DC), CD4+ T  cells, CD8+ TL and IL-7, and culturing said one or more target antigens with the mixture for sufficient time to generate CD8+ TL having selective immune reactivity toward one or more target antigens. The invention further provides a method of treating a patient having a disease mediated by a pathologically aberrant cell. The method consists of administering an effective amount of a CD8+ TL produced by the methods of the invention having antigenic specificity for, and/or selective cytolytic activity toward a pathologically aberrant cell.
SLT (Selective Laser Trabeculoplasty) uses the Nd:YAG-Lasers (wavelength 532nm, Q-switched, frequency-doubled). Thanks to the low laser energy used and the short duration of treatment, only pigmented cells of the trabecular meshwork are targeted and selectively treated. Neighboring, non-pigmented cells and tissue are spared collateral and thermic damage, the architecture of the trabecular meshwork remains intact. The SLT procedure uses less than 1% of the energy of the ALT procedure with an extremely low pulsation duration.

Several studies confirm the effective IOD reduction of SLT and rate the procedure as an relatively safe and effective therapy for glaucoma. Also repeated use of the SLT procedure is considered as meaningful. Meanwhile the SLT procedure is used as primary and supplementary treatment of glaucoma and study confirmed that the SLT procedure was just as effective as administration of Latanoprost in reducing IOD in newly-diagnosed glaucoma.
BACKGROUND: Vascular surgery carries a high risk of post-operative cardiac complications. Recent studies have shown an association between asymptomatic left ventricular systolic dysfunction and increased risk of major adverse cardiovascular events (MACE). This systematic review aims to evaluate the prognostic value of left ventricular function as determined by left ventricular ejection fraction (LVEF) measured by resting echocardiography before vascular surgery.
METHODS: This review conformed to PRISMA and MOOSE guidelines. PubMed, OVID Medline and Cochrane databases were searched from inception to 27 October 2022. Eligible studies assessed vascular surgery patients, with multivariable-adjusted or propensity-matched observational studies measuring LVEF via resting echocardiography and providing risk estimates for outcomes. The primary outcomes measures were all-cause mortality and congestive heart failure at 30 days. Secondary outcome included the composite outcome MACE.
RESULTS: Ten observational studies were included (4872 vascular surgery patients). Studies varied widely in degree of left ventricular systolic dysfunction, symptom status, and outcome reporting, precluding reliable meta-analysis. Available data demonstrated a trend towards increased incidence of all-cause mortality, congestive heart failure and MACE in patients with pre-operative LVEF <50%. Methodological quality of the included studies was found to be of moderate quality according to the Newcastle Ottawa Checklist.
CONCLUSION: The evidence surrounding the prognostic value of LVEF measurement before vascular surgery is currently weak and inconclusive. Larger scale, prospective studies are required to further refine cardiac risk prediction before vascular surgery.
The present invention relates to a soap using wild cultivated ginseng and a manufacturing method thereof. More specifically, the present invention relates to a soap using the wild cultivated ginseng, the soap which improves a prevention effect of skin diseases, a skin care effect, an anti-allergy effect, a removing effect of skin keratinocyte, and a moisturizing effect in terms of soap effects by adding a wild cultivated ginseng extract extracted from the wild cultivated ginseng that is a traditional oriental medicine material to the soap, thereby manufacturing a wild cultivated ginseng extract-added soap, and a manufacturing method of the soap using the wild cultivated ginseng. The method of the present invention comprises: containing an ordinary soap base in the soap to manufacture the soap containing the ordinary soap base; and containing 0.1 to 10 wt% of the wild cultivated ginseng extract in the soap based on the total weight of the soap to manufacture the soap containing the wild cultivated ginseng extract, wherein the wild cultivated ginseng extract is prepared by grinding the wild cultivated ginseng, mixing black sugar, honey and the ground wild cultivated ginseng at a weight ratio of 10:5:1 to obtain a mixture; aging the mixture at 16 to 18C for 5 days; and ultrasonic extracting the aged mixture at the temperature of 70 to 80C. Existing soaps threaten consumer safety and environmental friendliness aspects with regard to life environment of modern people since the soaps have mostly been comprising chemical components as components until now. Therefore, the present invention has manufactured a functional soap using the wild cultivated ginseng extract of which efficacy has been recognized as an eco-friendly material, a global food or a functional food. Panax ginseng maintains fame of a global special product due to geology environmental positions such as definite division of seasons, and main active ingredients of Panax ginseng are known to be a complex carbohydrate (a complex of alcohol or phenol and sugar) that is called as saponin or ginsenoside. Wood-cultivated ginseng (wild cultivated ginseng) has continuously been known to contain a larger amount of ginsenoside than Panax ginseng (ordinary ginseng). The method according to the present invention manufactures a functional soap having improved effects in skin care, cleaning, face washing, whitening and various skin diseases, and an effect of recovering a barrier function of damaged skin as a functional soap containing the wild cultivated ginseng extract including such functional materials.
Lenalidomide has been successfully used in patients with MDS in several studies. A small proportion of patients with MDS and del(5q) developed leukemia while treated with Lenalidomide. Up to now it is unknown what patients are at risk to progress while being treated with Lenalidomid. Therefore it is planned to examine not only the traditional clinical parameters like disease status and proportion of blasts, but also cytogenetic findings, gene expression, antiangiogenic effect, marrow fibrosis, mesenchymal stem cell as well as mitochondrial DNA mutation at baseline and in the course of the study performed by central laboratories. Moreover, long-term data are required, e.g., with regard to the development of AML. Therefore, it is planned to collect data from all patients with MDS and del 5q (isolated, blast count \<5%) in whom treatment with lenalidomide is the best therapeutic option according to the investigator's assessment in a structured fashion.